Drug Type Gene therapy, Hematopoietic stem cell therapy |
Synonyms- |
Target- |
Mechanism- |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hemophilia A | Phase 1 | - | 01 Feb 2021 |
Phase 1 | 4 | mxjbyukfww(qsixiabmwy) = The HSCT procedure was well tolerated. Neutrophil and platelet engraftment occurred at 10-12 and 12-15 days after HSCT and the duration of severe neutropenia and thrombocytopenia was 7-11 and 1-4 days, respectively. There were no bleeding episodes. No Grade >2 non-hematological toxicities occurred during the engraftment period. khkvkxdeov (lhwhlccfha ) | Positive | 23 Apr 2024 |